UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 171

Sortiert nach

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors

Investigational new drugs, 2023-06, Vol.41 (3), p.421-430

2023

Volltextzugriff (PDF)

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Breast cancer research and treatment, 2018-02, Vol.167 (3), p.671-686

2018

Volltextzugriff (PDF)

Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer

Clinical advances in hematology & oncology, 2023-03, Vol.21 (3), p.125

Hamilton, Erika P

2023

Volltextzugriff (PDF)

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

JAMA oncology, 2019-03, Vol.5 (3), p.393

2019

Volltextzugriff (PDF)

Availability of Experimental Therapy Outside Oncology Randomized Clinical Trials in the United States

Journal of clinical oncology, 2010-12, Vol.28 (34), p.5067-5073

2010

Volltextzugriff (PDF)

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Clinical cancer research, 2019-06, Vol.25 (12), p.3508-3516

2019

Volltextzugriff (PDF)

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review

JAMA oncology, 2021-12, Vol.7 (12), p.1873

2021

Volltextzugriff (PDF)

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

Molecular cancer therapeutics, 2021-08, Vol.20 (8), p.1442-1453

2021

Volltextzugriff (PDF)

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER + /HER2 - Advanced Breast Cancer

Clinical cancer research, 2018-08, Vol.24 (15), p.3510-3518

2018

Volltextzugriff (PDF)

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Clinical cancer research, 2024-05, Vol.30 (10), p.2233

2024

Volltextzugriff (PDF)

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer

Gynecologic oncology, 2020-09, Vol.158 (3), p.631-639

2020

Volltextzugriff (PDF)

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

Molecular cancer therapeutics, 2021-10, Vol.20 (10), p.1988-1995

2021

Volltextzugriff (PDF)

The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage

Cancer discovery, 2022-07, Vol.12 (7), p.1620-1624

2022

Volltextzugriff (PDF)

Breaking Barriers: Integrating Germline Testing With Oncology Care

JCO oncology practice, 2024-02, Vol.20 (2), p.157

2024

Volltextzugriff (PDF)

Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study

Clinical breast cancer, 2021-12, Vol.21 (6), p.539-551

2021

Volltextzugriff (PDF)

VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Future oncology (London, England), 2024-07, p.1-9

2024

Volltextzugriff (PDF)

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

Cancer discovery, 2024-02, Vol.14 (2), p.240

2024

Volltextzugriff (PDF)

A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer

Targeted oncology, 2021-09, Vol.16 (5), p.569-589

2021

Volltextzugriff (PDF)

Safety of Bevacizumab in Patients with Metastatic Breast Cancer

Oncology, 2011-01, Vol.80 (5-6), p.314-325

2011

Volltextzugriff (PDF)

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

JCO precision oncology, 2021-11, Vol.5, p.1297

2021

Volltextzugriff (PDF)

How can we optimize treatment of HER2-positive metastatic breast cancer?

Oncology (Williston Park, N.Y.), 2013-03, Vol.27 (3), p.180, 182-182

2013

Volltextzugriff (PDF)

Prevalence and impact of correlative science in breast cancer phase II trials

Breast cancer research and treatment, 2013-06, Vol.139 (3), p.845-850

2013

Volltextzugriff (PDF)

CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers

Journal of the National Comprehensive Cancer Network, 2015-08, Vol.13 (8), p.1005

2015

Volltextzugriff (PDF)

HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS1097-TPS1097

2021

Volltextzugriff (PDF)

1 – 25 von 171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(162)

Publikationsform

Artikel
(169)
Texte
(2)

Sprache

Englisch
(171)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(45)
Humans
(42)
Oncology
(36)
Female
(35)
Middle Aged
(20)
Aged
(17)
Breast Neoplasms - Drug Therapy
(17)
Adult
(15)
Tumors
(15)
Breast Neoplasms - Pathology
(14)
Breast Cancer
(13)
Metastasis
(12)
General & Internal Medicine
(10)
Male
(10)
Medicine, General & Internal
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Cancer Therapies
(9)
Immunotherapy
(9)
Biological And Medical Sciences
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

Availability of Experimental Therapy Outside Oncology Randomized Clinical Trials in the United States

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER + /HER2 - Advanced Breast Cancer

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage

Breaking Barriers: Integrating Germline Testing With Oncology Care

Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study

VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer

Safety of Bevacizumab in Patients with Metastatic Breast Cancer

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics

How can we optimize treatment of HER2-positive metastatic breast cancer?

Prevalence and impact of correlative science in breast cancer phase II trials

CHAMBER: A Regional Performance Improvement CME Initiative for Breast Cancer Health Care Providers

HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress)

Suchergebnisse filtern